Which Comes First, Nonalcoholic Fatty Liver Disease or Arterial Hypertension?

Julia A Golubeva; Anna F Sheptulina; Anastasia Yu Elkina; Ekaterina O Liusina; Anton R Kiselev; Oxana M Drapkina

doi:10.3390/biomedicines11092465

Which Comes First, Nonalcoholic Fatty Liver Disease or Arterial Hypertension?

Biomedicines. 2023 Sep 5;11(9):2465. doi: 10.3390/biomedicines11092465.

Authors

Julia A Golubeva¹, Anna F Sheptulina^{1

2}, Anastasia Yu Elkina^{1

3}, Ekaterina O Liusina¹, Anton R Kiselev⁴, Oxana M Drapkina^{1

2}

Affiliations

¹ Department of Fundamental and Applied Aspects of Obesity, National Medical Research Center for Therapy and Preventive Medicine, 101990 Moscow, Russia.
² Department of Therapy and Preventive Medicine, A.I. Evdokimov Moscow State University of Medicine and Dentistry, 127473 Moscow, Russia.
³ Department of Intermediate Level Therapy, Saratov State Medical University, 410012 Saratov, Russia.
⁴ Coordinating Center for Fundamental Research, National Medical Research Center for Therapy and Preventive Medicine, 101990 Moscow, Russia.

Abstract

Non-alcoholic fatty liver disease (NAFLD) and arterial hypertension (AH) are widespread noncommunicable diseases in the global population. Since hypertension and NAFLD are diseases associated with metabolic syndrome, they are often comorbid. In fact, many contemporary published studies confirm the association of these diseases with each other, regardless of whether other metabolic factors, such as obesity, dyslipidemia, and type 2 diabetes mellites, are present. This narrative review considers the features of the association between NAFLD and AH, as well as possible pathophysiological mechanisms.

Keywords: hypertension; non-alcoholic fatty liver disease; steatohepatitis.

Publication types

Review

Grants and funding

23-45-10030/Russian Science Foundation